Advanced Solid Tumors | Norton Healthcare

Indication: Advanced Solid Tumors

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Sponsor: OncoC4, Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.